Progress of anti-angiogenic therapy for brain tumors : new modality and resolution of the resistance

本研究旨在解决这种耐药性，并寻找新一代针对胶质母细胞瘤内皮细胞的抗血管生成疗法。胶质母细胞瘤抗血管生成治疗的解决方案：使用CPT-11的节律治疗对胶质瘤生长有效，没有全身副作用(J神经肿瘤学，2010)。建立持续应用血管内皮生长因子抗体治疗的胶质母细胞瘤复发小鼠模型(脑肿瘤病理学杂志，J Oncology杂志，2010)。在该模型中，SDF-1的特异性CXCR7抑制剂CCX771和LMWH可抑制VEGF抗体治疗后的复发。3.与单独接种肿瘤细胞相比，肿瘤内皮细胞和肿瘤细胞联合接种对胶质瘤生长的抑制作用更强。

This study was designed to resolve the resistance and find a new generation anti-angiogenic therapy targeting glioblastoma endothelial cells.1. Solution of anti-angiogenic treatment for glioblastoma : Metronomic treatment using CPT-11 was effective to glioma growth without systemic side effect (J Neuro-oncology, 2010).2. Glioblastoma recurrence mouse model with continuous VEGF antibody treatment was established (Brain Tumor Pathol 2010, J Oncology 2010). With this model, Specific CXCR7 inhibitor, CCX771 and LMWH, antagnosit of SDF-1, inhibited recurrence after VEGF antibody treatment.3.Vaccination with tumor endothelial cells and tumor cells inhibited glioma growth strongly compared to vaccination with tumor cell alone.